Linezolid, an oxazolidinone antibiotic, is the first representative of a truly novel class and efficacious in serious or problematic infections for which there are few therapeutic alternatives. The intrinsic properties of linezolid make it an attractive candidate for the treatment of chronic osteomyelitis. Although generally well tolerated, gastrointestinal adverse effects are relatively common and thrombocytopenia and a slight increased risk for anemia were evident at ≧ 2 weeks of linezolid therapy. We report a case with hematologic abnormalities were consistent with reversible, duration-dependent event. Appropriate weekly hematologic monitoring is warranted with linezolid therapy.